Dovipa: Immunotherapy and vitamin D with chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether combining the immunotherapy dostarlimab with vitamin D3 and standard chemotherapy (mFOLFIRINOX) can help people with stage IV pancreatic cancer. It aims to see if this new approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic pancreatic cancer that has not been treated yet (no prior chemotherapy for stage IV).
- You are between 18 and 75 years old.
- You are in good enough health to be up and active (ECOG score 0 or 1).
- Your tumor can be measured on scans and you are willing to have a fresh biopsy of the tumor.
- Your blood counts, liver and kidney function are within acceptable levels.
- You agree to use effective birth control during and for 6 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a vitamin A derivative (ATRA), an immune booster (SDK002), chemotherapy, and an immunotherapy (anti-PD-1) to treat advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow the disease.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
Hear when a new Pancreas Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.